• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Meena U Rajagopal, Yetrib Hathout, +7 authors Brian R Rood
  • Biology, Medicine
  • Proteomics
  • 2011 (First Published: 1 March 2011)
  • The aims of this study were to demonstrate the feasibility of centrally collecting and processing high-quality cerebrospinal fluid (CSF) samples for proteomic studies within a multi-center consortiumContinue Reading
  • Katherine E. Warren, Sri Gururangan, +11 authors Larry E. Kun
  • Medicine
  • Journal of Neuro-Oncology
  • 2011 (First Published: 1 February 2012)
  • To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated withContinue Reading
  • Joseph S. Pekala, Sri Gururangan, James M. Provenzale, Srinivasan Mukundan
  • Medicine
  • AJNR. American journal of neuroradiology
  • 2006 (First Published: 1 March 2006)
  • Although these entities are histologically similar, recent advances in molecular genetics have allowed the distinction of central nervous system extraosseous Ewing sarcoma (CNS-EES) from centralContinue Reading
  • Sri Gururangan, Richard Sposto, Mitchell S Cairo, Anna T. Meadows, Jonathan L Finlay
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2000 (First Published: 10 May 2000)
  • PURPOSE To examine the impact of initial CNS involvement on outcome and patterns of failure in patients with disseminated small noncleaved-cell lymphoma and B-cell leukemia who were treated in fourContinue Reading
  • Mark W Kieran, Roger J. Packer, +17 authors Larry E. Kun
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2007 (First Published: 20 July 2007)
  • PURPOSE A dose-escalation phase I and pharmacokinetic study of the farnesyltransferase inhibitor lonafarnib (SCH66336) was conducted in children with recurrent or progressive CNS tumors. PrimaryContinue Reading